Categories

October is breast cancer awareness month and according to the American Cancer Society, 1 in 8 U.S. women will be diagnosed with breast cancer in their lifetime.  In 2018, about 266,000 new cases of breast cancer will be diagnosed and 41,000 women will die from this disease. Although good progress is being made in the…

Continue Reading

September is Prostate Cancer Awareness Month. According the American Cancer Society, more than 165,000 men will be diagnosed with prostate cancer this year, and there are over 2.9 million men in the United States who have been previously diagnosed with prostate cancer that are alive today. That’s enough men to fill Yankee Stadium 58 times!…

Continue Reading

The biomedical innovation now happening in the molecular diagnostics industry is making it possible for clinicians to answer their patients’ four most pressing questions about their health.  Will I get a disease? Do I have a disease?  Should I treat my disease? How should I treat my disease?  Importantly, more than ever before, clinicians now…

Continue Reading

Mental Health Month, Depression and GeneSight®    The GeneSight® genetic test has produced exciting news for patients diagnosed with depression.  A landmark study showed that the GeneSight Test led to significant improvement in mental health outcomes for patients with major depressive disorder (MDD).  Read the full news release here.  This exciting, new data for GeneSight was presented at…

Continue Reading

ColonCancerPoster_Thumbnail

In hereditary colon cancer, knowledge is power!  During the month of March, Myriad Genetics is demonstrating a strong commitment to preventing hereditary colon cancer as part of National Colorectal Cancer Awareness Month.  Colon cancer is third most commonly diagnosed cancer in both men and women in the United States and kills one person every 10 minutes. More than 140,000…

Continue Reading

The U.S. Food and Drug Administration (FDA) has approved BRACAnalysis CDx® for use as a companion diagnostic to identify patients with HER2- metastatic breast cancer who are candidates for treatment with AstraZeneca’s PARP inhibitor, Lynparza®(Olaparib). BRACAnalysis CDx is the only FDA-approved test for use in this important indication. The approval of BRACAnalysis CDx underscores the need for  patients with…

Continue Reading

It is estimated that 19 million people suffer from “year round” depression. If every American with depression lived in one state it would be the country’s fifth largest state. For many of these people, their depression will get worse in the winter months. Additionally, approximately 11 million Americans suffer from a severe winter form of…

Continue Reading

Shortly after I was born, my father was diagnosed with Hodgkin’s lymphoma and he passed away when he was just 29 years old.  Losing my dad when I was so young is what ultimately led me to becoming a cancer genetic counselor focusing on cancer prevention…which begins with knowing your family history. I came to…

Continue Reading

At Myriad, we are committed to defeating breast cancer and we know that decisions matter when it comes to breast cancer. We have several genetic tests that can help women with breast cancer, but can also help others with preventing breast cancer. Currently, myRisk now with riskScore, EndoPredict, BRACAnalysis CDx, and myChoice HRD are genetic…

Continue Reading

When diagnosed with prostate cancer, genetic precision can guide decisions between patients and their doctors. Click below to learn more and download this infographic. Learn how a hereditary cancer risk assessment is an important option for prostate cancer patients during Prostate Cancer Awareness Month.  

Continue Reading